DiaKine Therapeutics Products

Lisofylline (LSF) is a synthetic small molecule with novel anti-inflammatory properties. LSF has demonstrated that it can effectively prevent type 1 diabetes in preclinical models. LSF has shown to improve cellular mitochondrial function and to block interleukin 12 (IL-12) signaling and STAT-4 activation in target cells and tissues. IL-12 and STAT 4 activation are important pathways linked to inflammatory damage to insulin producing cells. Therefore, LSF and the next generation of orally bioavailable immune modulators offer the promise of providing a new therapeutic approach to treat type 1 or type 2 diabetes. Studies further indicate that LSF also directly reduces glucose-induced changes in human kidney cells suggesting that LSF and orally bioavailable immune modulators have the potential to treat diabetic nephropathy. Activation of STAT4 has also been linked to insulin resistance and atherosclerotic cardiovascular disease. Therefore, Diakine targeted small molecule STAT4 immune modulators have the potential to reduce the burden of CVD in people with diabetes.

Lisofylline and Next Generation Orally Active Anti-Inflammatory Immune Modulators